Iaso Bio to Present Eque-cel (Idecabtagene Vicleucel) Data in Progressive Multiple Sclerosis at 2025 ANA and ECTRIMS Conferences

Sep 12, 2025 10:05 CST Updated 10:05

IASO Biotechnology

Cancer Treatment New Drug Developer

On September 12, 2025, IASO Bio announced its self-developed fully human BCMA-targeted CAR-T cell therapy.Research results on the use of Eque-cel (Idecabtagene Vicleucel) Injection for treating Progressive Multiple Sclerosis (PMS) will be successively presented at the 2025 American Neurological Association (ANA) Annual Meeting and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Conference., which were released in the form of a poster and an oral presentation, respectively.

Meeting Name：2025 Annual Meeting of the American Neurological Association

Report Type:Poster

Reporting Location:Baltimore, USA

Report Time:September 15, 2025

Abstract Number:M110

Meeting Name:2025 ECTRIMS Congress

Report Type:Oral Report

Reporting Location:Barcelona, Spain

Report Time:September 26, 2025

Abstract Number:ECTRIMS25-1626

Reporter:Professor Qin Chuan from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

This research achievement is based on an investigator-initiated clinical study (IIT, NCT04561557) led by Professor Wang Wei's team from the Department of Neurology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The study aims to evaluate the efficacy and safety of Icaritin Injection in treating relapsed or refractory antibody-mediated idiopathic inflammatory neurological diseases.

This study enrolled five patients with progressive multiple sclerosis (PMS), including one patient with primary progressive MS (PPMS) and four patients with secondary progressive MS (SPMS).

Efficacy

The mean Expanded Disability Status Scale (EDSS) score improved from 6.2 at baseline to 5.0 at the last visit.
The average 9-HPT time decreased from 51.3 seconds (left) and 40.9 seconds (right) to 35.9 seconds and 27.8 seconds, respectively;
The average T25-FW time decreased from 27.3 seconds to 15.7 seconds;
MRI revealed no new or enlarging T1 gadolinium-enhanced lesions or T2 hyperintense lesions in any of the patients.

Safety

Four out of five patients experienced transient Grade 1 CRS;
No ICANS or other neurotoxicity reactions were observed after infusion;
Only ≥3 grade neutropenia and lymphocyte count decrease were observed, without occurrence of ≥3 grade anemia or thrombocytopenia.

Conclusion：Targeted BCMA CAR-T cells demonstrate good tolerability and significant efficacy in treating progressive multiple sclerosis, specifically showing marked improvement in patients' physical functions, along with the disappearance of oligoclonal bands (OCBs) and κ free light chains in cerebrospinal fluid.

About Eque-cel Injection

Eque-cel (Idecabtagene Vicleucel) Injection is a CAR-T cell therapy targeting B-cell maturation antigen (BCMA). It uses lentivirus as a gene vector to transfect autologous T cells. The CAR comprises a fully human scFv, CD8a hinge and transmembrane domain, 4-1BB co-stimulatory molecule, and CD3ζ activation domain. Based on rigorous molecular structure screening and comprehensive in vivo and in vitro functional evaluation, Eque-cel Injection demonstrates rapid and potent efficacy with remarkable in vivo persistence, enabling patients to achieve deep and durable remission.

About IASO Bio

IASO Bio, established in 2017, is a leading biopharmaceutical company focusing on the research, production, and sales of innovative cell therapies. The company builds its innovation foundation on the development of hematological tumor cell drugs and expands into the fields of autoimmune diseases and antibody-based drugs, possessing full-process capabilities from early drug discovery, clinical development, regulatory submission to commercialization.

The company currently has more than 10 innovative drug candidates at various stages of development, including IASO Bio's self-developed, world-first fully human CAR-T product, Equecabtagene Autoleucel Injection (Forblood), which targets BCMA.^®) was approved for marketing by the National Medical Products Administration (NMPA) in June 2023.For the treatment of relapsed or refractory multiple myeloma (R/R MM). In addition, the product has also been approved for marketing in Macao, China; its marketing applications are currently under review in Hong Kong, China, Singapore, and Saudi Arabia; and it has received orphan drug designation in South Korea. Registration work in other countries is also proceeding steadily.Its frontline indication for the treatment of 2-3 line multiple myeloma (MM) has entered Phase III clinical trials. In addition, the new drug clinical trial applications (IND) for Ixazomib Injection for multiple autoimmune diseases have been approved in China and the United States. Meanwhile, the dual-target (CD19/CD22) product CT120 for lymphoma has been approved to enter Phase II clinical trials.

In addition to cellular therapy products, IASO Bio's fully human anti-CD19 antibody product, IASO-782, has received IND approval in China and the United States for the treatment of multiple autoimmune diseases, with further indications for additional autoimmune conditions still under exploration.

The company has successively reached global business development licensing or R&D collaborations with overseas cell therapy companies Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, actively exploring the development of next-generation cell therapy products.

IASO Bio, with its strong management team and execution capabilities, innovative product pipeline, self-owned GMP manufacturing, and advanced clinical development capabilities, is committed to bringing transformative and accessible innovative therapies and the hope of a cure to patients in China and around the world. For more information, please visit the company’s official website: www.iasobio.com or LinkedIn page: www.linkedin.com/company/iasobiotherapeutics.